The results sheet that never ran

The full results sheet of a half marathon held in China in March has never appeared in any newspaper. The winner's name is Ruti Aga. What survived from that sheet was not a time — it was a number: six. Six years of ineligibility, announced by the Athletics Integrity Unit (AIU) on Thursday. And the document that added four of those six years was not a blood sample; it was a prescription — written by a man with no medical registration, on behalf of a clinic that did not exist, on an "old prescription pad" that the clinic flatly disowned.

Three verification failures. On one piece of paper.

My habit in such cases is to write the date first, then the substance, then the dose and the route, and the statement last. Here there is only one date — 10 September, from which the provisional suspension runs. The substance is methylprednisolone. And the most important thing in the statement is that this is not a steroid case, although most headlines called it one. That error places the entire case on the wrong footing.

Five paragraphs of a statement, and the gaps between them

The AIU statement is short. It stacks two sanctions: two years for presence, four for tampering. The charge rests on a sample taken after Aga won a half marathon in China in March. The defence cited a knee injury and methylprednisolone as treatment. The prescription was written by a family member described as a "doctor" who held no registration; the clinic named on the prescription did not exist; and the clinic disowned any connection to the "old pad" that was invoked.

What the statement does not contain matters as much. No mark from the March race. No splits, no field depth, no race name, no end date for the ban, no scope of disqualification. I have learned to trust the quiet note before the loud quote — and the quiet note here says we have a result with no number attached to it, and a sanction with no performance context.

What survives on the performance record is older: the 2026 Tokyo Marathon title, and three second-place finishes at World Marathon Majors. Public records place her best around 2:18:34 at Berlin 2026 and roughly 2:20:40 at Tokyo 2026. Those figures are not in the AIU statement, so treat them as pending verification — but without them it is hard to grasp that this is an athlete who sat in the 2:18–2:20 band, top ten or twelve in the world, and still not automatically top three in her own country.

S9: the category the headline got wrong

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List. And the defining condition of that class is that it is prohibited in-competition only — by injection, oral or rectal route. A therapeutic dose taken out of competition is not, by itself, a violation.

This is the technical hinge that separates the case from a steroid story: the question is route and timing, not the drug. A therapeutic knee injection is entirely lawful if it is documented, if the route is clean, and if the washout period is counted against the race date. It becomes a violation when residues are present in a sample taken in competition. Testing windows at road races open at 23:59 the day before the race — so an injection given days earlier can still be caught.

One more thing follows, and it should precede any sanction analysis: there is no established evidence that glucocorticoids enhance marathon performance. They reduce pain and inflammation. Reducing pain means masking injury, not going faster. Those who file this as a "steroid" case place it in a category where it does not belong — and then the proportionality of the sanction stops making sense.

A knee, a needle, and a timetable nobody kept

The knee-injury explanation is plausible on the ground and fatal in law. Knee synovitis is routine in high-volume marathon preparation, and intra-articular methylprednisolone is standard sports-medicine practice. That plausibility is exactly what turns the case: if the treatment had genuinely happened and the records existed, the defence would have been built on real documents. The moment the prescription was manufactured, the only defence that could have worked was destroyed.

A properly managed athlete has two routes: obtain a Therapeutic Use Exemption, or observe the route-specific washout and select the race date accordingly. Neither appears here. What appears is an athlete operating without a credentialed team physician, treated inside her family, whose "medical support" is not an institution's protocol but a relative's good intentions.

And here my 2026 file opens itself. Across eleven days at Delhi 2026 I watched the 4x400 girls celebrate on that track; five months later six athletes were suspended and the case ran to 2026. That experience gave me a habit — examine the federation's testing architecture first, the athlete's mistake second. Here the federation is not the AIU but the Ethiopian national structure, and the statement says not one word about it. Still, three verification failures are enough to show that somewhere in that structure a door has been left open.

Two plus four: what the arithmetic says

The sanction architecture is standard, not exceptional. Two years for presence is the norm where the substance is Specified and intent is not proven. Four years for tampering is the Code's standard sanction. Add them — six.

Two things follow. First, the panel rejected the no-significant-fault mitigation. Had the prescription been genuine, or the dose and route cleanly documented, two years could have been cut sharply, possibly to a reprimand. Second, the four-year tampering sanction means the panel treated the document fraud as fully culpable.

Note a paradox here, because it will become precedent: forged documentation is itself circumstantial evidence of concealment, yet it did not aggravate the presence sanction. The panel kept the two offences in separate boxes — two for the drug, four for the paper. Those who assume the forgery "doubled" the ban are misreading it. The forgery tripled it, and simultaneously destroyed everything that might have survived even inside a two-year absence.

Backdating to 10 September is not relief. Time served under provisional suspension counts against the ban; the athlete gains nothing in real terms. A CAS appeal window exists — typically about three weeks from the reasoned decision — but document-based findings are hard to overturn. There is no visible ground here either, because no paper survives against a clinic that has disowned the pad.

Thirty-two now, thirty-eight on return

Aga is 32. Six years from 10 September puts the return at roughly 38. In Ethiopian women's marathoning, that age opens no doors. Where several athletes run under 2:16 in the same pool, a 2:18–2:20 performer is not automatically selectable for her national team — and a 38-year-old with a doping record is not selectable at all.

The ban is technically six years and practically the end of a career. The 2028 Olympic cycle is gone in full. The three World Marathon Major second places — among the hardest achievements in the sport — will remain on the record of a woman no sponsor will sign. Distance-running sponsorship is thin to begin with; a sanction takes it close to zero.

One correction, because it is being printed wrongly: the 2026 Tokyo title has not been stripped automatically. The violation is anchored to a later March race, and absent a finding of earlier use, results before that date are not automatically annulled. Yes, the race at which the sample was collected will almost certainly lose its result and prize money, and ranking points after that date go with it — standard AIU practice — but the statement does not state the scope. The record book remembers what the press box forgets: these are two separate things, a runner's career and an administrative file.

China's label circuit: appearance money and testing money in the same race

The geography is part of the story. The March race was in China, and the Chinese road-racing circuit is a familiar economic tier for East African marathoners — decent appearance fees between Majors, low risk, few races. For a 2:18 athlete the model is rational: two or three Majors a year, a handful of label races in between to cover costs.

That same tier has become the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are now colliding in the same races. Where the money is large and the East African elite field dense, the samples are also most numerous. Dismissing these as "small races" leaves reporting with no context when a big name is caught there.

Do not read this athlete's economy in Indian terms. There is no railway quota, no Services team, no PSU job as a safety net. The Ethiopian and Kenyan distance-running structure runs on clubs, agents and appearance fees, with agents running training camps and medical support staying informal. In that model the weakest link is not doping but medical governance — and that is the link that broke here.

One question the statement does not answer and which should be asked: who advised on that prescription? The AIU named only the family member. Whether the agent or management was investigated is not public. When an athlete has no access to a doctor, whoever she takes advice from becomes her "system."

The outside habit of misreading

The first confusion is direct: calling this a steroid case. It does double damage. One, the reader assumes a speed-enhancing drug was in play, which is unproven for glucocorticoids. Two, the proportionality of the sanction becomes inexplicable — six years for a drug that reduces pain?

The second confusion is cleverer and therefore more dangerous: that the AIU is targeting East African road runners. The numbers may show something real — tampering charges recur in this region's cases — but in this case four of the six years came from paper, not from the drug. If the bulk of the sanction comes from a forged document, the "hunted for their medicine" story weakens. What survives is more uncomfortable: some athletes have so little institutional support that hiding a mistake looks cheaper than correcting it.

The third, and most common, is to treat a ban as a full stop. A ban is not a full stop; it is a long, awkward comma — but not every comma returns to its sentence. At 32, a six-year comma is a sentence that ends complete and unfinished at once.

The next internal signal

When the stadium empties, I stay for the names on the sheet. On my sheet for this case there are three dates: that March race, 10 September, and a blank where the end of the ban should be written. Anyone citing this case later should watch three things — whether the March result is formally annulled, whether the AIU begins counting document verification as a distinct case family, and whether the Ethiopian federation produces even one sentence. Any of the three will point to the shape of the next case. And the next time a marathoner takes a needle in the knee, the question will not be whether the needle went in — it will be who kept the paper.